(FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -44.78%883.48M | -48.05%660.43M | -62.58%345.18M | 9.96%322.38M | 33.87%1.6B | --1.27B | 44.41%922.38M | --293.19M | 69.30%1.2B | 147.64%638.72M |
Operating income | -44.78%883.48M | -62.58%345.18M | 33.87%1.6B | 44.41%922.38M | 69.30%1.2B | 147.64%638.72M | ||||
Cost of sales | 2.17%-523.76M | ---- | 8.66%-245.94M | ---- | 17.36%-535.39M | ---- | 6.24%-269.26M | ---- | -21.90%-647.83M | -31.47%-287.18M |
Operating expenses | 2.17%-523.76M | 8.66%-245.94M | 17.36%-535.39M | 6.24%-269.26M | -21.90%-647.83M | -31.47%-287.18M | ||||
Gross profit | -66.21%359.72M | -66.30%288.31M | -84.81%99.23M | 17.65%201.57M | 94.52%1.06B | 855.61M | 85.79%653.12M | 171.33M | 213.77%547.2M | 790.36%351.54M |
Administrative expenses | 20.76%-299.98M | ---- | 28.49%-142.02M | ---- | -10.32%-378.57M | ---- | -76.13%-198.6M | ---- | -36.73%-343.15M | -25.34%-112.76M |
Impairment and provision | 22.75%-11.28M | ---- | ---- | ---- | 79.36%-14.6M | ---- | ---- | ---- | -6,504.20%-70.73M | ---- |
-Other impairment is provision | 22.75%-11.28M | ---- | ---- | ---- | 79.36%-14.6M | ---- | ---- | ---- | -6,504.20%-70.73M | ---- |
Special items of operating profit | -13.08%586.56M | ---- | 36.09%461.34M | ---- | 54.92%674.87M | ---- | 168.06%339M | ---- | 212.36%435.63M | 144.85%126.47M |
Operating profit | -52.83%635.02M | -43.30%616.38M | -47.25%418.55M | 14.46%181.36M | 136.60%1.35B | 1.09B | 117.25%793.53M | 158.45M | 820.42%568.95M | 30,958.93%365.25M |
Financing cost | -3.26%-105.69M | ---- | 1.03%-54.95M | ---- | -37.68%-102.36M | ---- | -47.16%-55.52M | ---- | 3.66%-74.34M | 9.54%-37.73M |
Share of profits of associates | -6,413.03%-31.5M | ---- | -181.47%-6.83M | ---- | -97.00%499K | ---- | -114.02%-2.43M | ---- | -95.16%16.63M | -87.33%17.32M |
Share of profit from joint venture company | 48.40%-31.38M | ---- | 95.63%-604K | ---- | -152.97%-60.82M | ---- | -113.55%-13.82M | ---- | -66.63%114.83M | -69.54%101.94M |
Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---1.62B | ---1.78B |
Earning before tax | -60.59%466.45M | -50.65%356.17M | 219.65%1.18B | 154.29%721.76M | -247.18%-989.11M | -408.58%-1.33B | ||||
Tax | 97.43%-6.91M | ---- | 91.65%-10.62M | ---- | -116.29%-269.09M | ---- | -80.16%-127.08M | ---- | -240.25%-124.41M | -1,112.36%-70.54M |
After-tax profit from continuing operations | -49.74%459.55M | -41.89%345.55M | 182.11%914.35M | 142.48%594.69M | -275.23%-1.11B | -429.40%-1.4B | ||||
Earning after tax | -49.74%459.55M | -41.89%345.55M | 182.11%914.35M | 142.48%594.69M | -275.23%-1.11B | -429.40%-1.4B | ||||
Minority profit | 830.52%55.98M | ---- | 684.48%42.36M | ---- | 57.89%-7.66M | ---- | -37.83%-7.25M | ---- | 21.36%-18.2M | 67.10%-5.26M |
Profit attributable to shareholders | -56.23%403.57M | -42.00%465.35M | -49.63%303.19M | 1.88%110.42M | 184.18%922.01M | 802.29M | 143.16%601.93M | 108.39M | -266.31%-1.1B | -416.27%-1.39B |
Basic earnings per share | -57.05%0.0557 | -43.17%0.0641 | -50.71%0.0417 | 185.39%0.1297 | 0.1128 | 143.99%0.0846 | -257.90%-0.1519 | -391.36%-0.1923 | ||
Diluted earnings per share | -57.05%0.0557 | -43.53%0.0637 | -51.06%0.0414 | 185.39%0.1297 | 0.1128 | 143.99%0.0846 | -258.73%-0.1519 | -393.59%-0.1923 | ||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data